32 completed, 10 unknown, 5 terminated, 4 recruiting. 55 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 55 | Completed 32, Unknown 10, Terminated 5, Recruiting 4, Withdrawn 3, Not yet recruiting 1 |
| Phase 2 | 12 | Unknown 5, Completed 3, Recruiting 2, Terminated 1, Withdrawn 1 |
Follow Brain Damage, Chronic: new trials by email Literature Review of Brain Damage, Chronic trials Research Report on Brain Damage, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy Tranexamic Acid (IV), Placebo - Cerebral Palsy, Hip Surgery Corrective | Phase 3 | Not yet recruiting | Murdoch Childrens Research Institute | 52 | 2026-11-01 | 2026-10-14 |
| Antenatal Magnesium Sulphate in High-Risk Preterm Patients Magnesium sulfate, Placebo - Cerebral Palsy, Magnesium Sulfate Overdose | Phase 3 | Recruiting | Cairo University | 138 | 2026-05-01 | 2026-04-13 |
| Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease [F-18]Flornaptitril - Alzheimer Disease, Chronic Traumatic Encephalopathy | Phase 3 | Recruiting | CereMark Pharma, LLC | 230 | 2025-07-01 | 2025-07-30 |
| Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy Magnetic Spinal Stimulation - Spastic Cerebral Palsy, Dysarthria | Phase 2 / Phase 3 | Unknown | Sociedad Argenttina de Neuromodulación | 20 | 2024-11-18 | 2023-11-21 |
| Wereables for Upper Limb Functionality in Hemiparesis WeFun-wearable activated, WeFun-wearable desactivated - Unilateral Cerebral Palsy | Phase 2 / Phase 3 | Recruiting | Universidade da Coruña | 40 | 2024-06-07 | 2025-03-12 |
| Efficacy of Extracorporeal Shock Wave Therapy in Children With Cerebral Palsy ESWT, Botulinum Toxin Type A, Serial Casting - Spasticity/Paresis, Cerebral Palsy | Phase 3 | Unknown | Kocaeli University | 40 | 2023-11-01 | 2023-11-18 |
| Therapeutic Photobiomodulation and Tretament of Spasticity Photobiomodulation, Institution's Standard Physiotherapy, Photobiomodulation Placebo - Muscle Spasticity, Cerebral Palsy | Phase 2 / Phase 3 | Completed | University of Nove de Julho | 12 | 2023-08-15 | 2026-05-01 |
| Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries Magnesium sulfate loading with maintenance dose, Magnesium sulfate loading dose only - Premature Birth, NEUROPROTECTION | Phase 2 / Phase 3 | Unknown | Zagazig University | 336 | 2023-01-20 | 2023-07-14 |
| Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy Botox® injection, Scopoderm® patches arm - Cerebral Palsy | Phase 3 | Terminated | Hospices Civils de Lyon | 23 | 2022-04-27 | 2026-01-30 |
| Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Placebo, Valbenazine - Dyskinesia, Cerebral Palsy | Phase 3 | Completed | Neurocrine Biosciences | 86 | 2022-04-15 | 2026-04-29 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Double-blind Comparative Randomized Multicenter Miotox (Botulinum toxin type A is a hemagglutinin complex), BOTOX® - Cerebral Palsy (CP) | Phase 3 | Completed | Innopharm LLC | 80 | 2021-10-15 | 2025-02-21 |
| Apomorphine in Severe Brain-injured Patients Apomorphine Hydrochloride 5mg/ml, Sodium chloride 9mg/ml - Disorder of Consciousness | Phase 2 / Phase 3 | Recruiting | University of Liege | 48 | 2021-06-18 | 2025-04-15 |
| Study of Thyroid Hormones in Prematures thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water - Transient Hypothyroxinemia of Prematurity (THOP) | Phase 3 | Withdrawn | New York Medical College | 2020-07-01 | 2019-04-24 | |
| A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy TEV-50717 - Cerebral Palsy, Dyskinetic | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 44 | 2020-02-04 | 2024-04-22 |
| Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE) I-ACQUIRE - High Dosage, I-ACQUIRE - Moderate Dosage, Usual & Customary Treatment (U&CT) - Perinatal Stroke, Hemiparesis | Phase 3 | Completed | Virginia Polytechnic Institute and State University | 216 | 2019-10-10 | 2026-06-01 |
| A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents TEV-50717, Placebo - Cerebral Palsy, Dyskinetic | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 63 | 2019-08-06 | 2023-09-08 |
| Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy Dysport Injectable Product - Cerebral Palsy | Phase 3 | Completed | Columbia University | 12 | 2018-12-12 | 2022-06-01 |
| Integrated Management of Pronation Deformity in Cerebral Palsy Botulinum toxin type A, Upper extremity orthoses, Home exercise program - Cerebral Palsy | Phase 3 | Completed | Kocaeli University | 35 | 2018-03-26 | 2020-04-16 |
| Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome Erythropoietin, Normal saline - Premature Infants, Intracranial Hemorrhages | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 400 | 2017-04-10 | 2017-10-02 |
Showing 20 of 55. Sign in to see all of them.
Cerebral Palsy (51) · Muscle Spasticity (17) · Stroke (7) · Premature Birth (5) · Brain Injuries, Traumatic (3) · Hemiplegia (3) · Intellectual Disability (3) · Leukomalacia, Periventricular (3) · Paresis (3) · Persistent Vegetative State (3) · Sialorrhea (3) · Brain Injuries (2) · Consciousness Disorders (2) · Intracranial Hemorrhages (2) · Multiple Sclerosis (2)
Brain Diseases (55) · Central Nervous System Diseases (55) · Nervous System Diseases (54) · Pathological Conditions, Signs and Symptoms (34) · Signs and Symptoms (30) · Neurologic Manifestations (28) · Musculoskeletal Diseases (19) · Muscle Hypertonia (17) · Muscular Diseases (17) · Neuromuscular Manifestations (17) · Cardiovascular Diseases (11) · Cerebrovascular Disorders (11) · Vascular Diseases (11) · Wounds and Injuries (8)
Botulinum Toxins, Type A (18) · Magnesium Sulfate (4) · Saline Solution (4) · abobotulinumtoxinA (4) · Occupational Therapy (2) · Physical Therapy Modalities (2) · Sodium Chloride (2) · Transcranial Direct Current Stimulation (2) · deutetrabenazine (2) · incobotulinumtoxinA (2) · rimabotulinumtoxinB (2) · 2-(4-ethoxybenzyl)-1-diethylaminoethyl-5-isothiocyanatobenzimidazole (1) · Alendronate (1) · Apomorphine (1) · Baclofen (1)
Allergan (4) · Kocaeli University (4) · Hospices Civils de Lyon (2) · Ipsen (2) · Merz Pharmaceuticals GmbH (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Cairo University (1) · CereMark Pharma, LLC (1) · Chaitanya Hospital, Pune (1) · Columbia University (1) · Department of Clinical Research and Innovation (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Flowonix Medical (1)
United States (20) · Poland (12) · France (9) · Russia (9) · Turkey (Türkiye) (9) · Hungary (6) · Spain (6) · Italy (5) · Ukraine (5) · United Kingdom (5) · Canada (4) · Israel (4) · Mexico (4) · Philippines (4) · South Korea (4)
Emily McCusker (2) · Nigar Dursun, MD (2) · Rozalina Dimitrova (2) · Adam Kirton, MD MSc FRCPC (1) · Ahmed M Kamel, M.D. (1) · Amro Alnemr, M.D. (1) · Anant E Bagul, M.S. (1) · Ariane Zoll (1) · Chad Yucus, MD (1)
PMID 36136523, PMID 18065878, PMID 18753646, PMID 19581264, PMID 19622997, PMID 20027029, PMID 22298950, PMID 25157725, PMID 25534356, PMID 26254839, PMID 26812925, PMID 27029628, PMID 27130143, PMID 27187300, PMID 27244862, PMID 27631386, PMID 28726270, PMID 31143877, PMID 31691605, PMID 33206382, PMID 33483965, PMID 34339951, PMID 34341153, PMID 34828772, PMID 35412036, PMID 36306168, PMID 36832460, PMID 40498248, PMID 42852504
2009 (1), 2018 (1), 2019 (1), R01HD021453 (1), U01HD043464 (1), U10HD021410 (1), U10HD021414 (1), U10HD027860 (1), U10HD027861 (1), U10HD027869 (1), U10HD027905 (1), U10HD027915 (1), U10HD027917 (1), U10HD034116 (1), U10HD034122 (1)